{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T07:36:16Z","timestamp":1677137776938},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s11886-019-1088-x","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T07:07:27Z","timestamp":1548659247000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndromes: a Review"],"prefix":"10.1007","volume":"21","author":[{"given":"Peter","family":"Khalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazal","family":"Kabbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"issue":"12","key":"1088_CR1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013e492.","journal-title":"Circulation"},{"issue":"11","key":"1088_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197\u2013206.","journal-title":"JAMA"},{"key":"1088_CR3","doi-asserted-by":"crossref","unstructured":"Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, et al. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. J Am Heart Assoc. 2016;5(10).","DOI":"10.1161\/JAHA.116.004080"},{"issue":"2","key":"1088_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/1755-5922.12169","volume":"34","author":"H Khoury","year":"2016","unstructured":"Khoury H, Lavoie L, Welner S, Folkerts K. The burden of major adverse cardiac events and antiplatelet prevention in patients with coronary or peripheral arterial disease. Cardiovasc Ther. 2016;34(2):115\u201324.","journal-title":"Cardiovasc Ther"},{"issue":"12","key":"1088_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350\u20137.","journal-title":"JAMA"},{"issue":"24","key":"1088_CR6","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1088_CR7","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","volume":"67","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC\/AHA\/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"1088_CR8","doi-asserted-by":"crossref","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non-st-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016, 134;(10):e123\u201355.","DOI":"10.1161\/CIR.0000000000000404"},{"issue":"1","key":"1088_CR9","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ccd.24776","volume":"82","author":"PT O'Gara","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;82(1):E1\u201327.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1088_CR10","doi-asserted-by":"crossref","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017, 2017;70(12):\u20131082.","DOI":"10.1016\/j.rec.2017.11.010"},{"issue":"1","key":"1088_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"issue":"5","key":"1088_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519\u201326.","journal-title":"Eur Heart J"},{"issue":"8","key":"1088_CR13","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood-2002-03-0954","volume":"102","author":"D Ardissino","year":"2003","unstructured":"Ardissino D, Merlini PA, Bauer KA, Galvani M, Ottani F, Franchi F, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood. 2003;102(8):2731\u20135.","journal-title":"Blood"},{"issue":"9","key":"1088_CR14","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2008-07-167411","volume":"113","author":"A Undas","year":"2009","unstructured":"Undas A, Szuldrzynski K, Brummel-Ziedins KE, Tracz W, Zmudka K, Mann KG. Systemic blood coagulation activation in acute coronary syndromes. Blood. 2009;113(9):2070\u20138.","journal-title":"Blood"},{"issue":"2","key":"1088_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1160\/TH07-07-0443","volume":"99","author":"J Orbe","year":"2008","unstructured":"Orbe J, Zudaire M, Serrano R, Coma-Canella I, Martinez de Sizarrondo S, Rodriguez JA, et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost. 2008;99(2):382\u20137.","journal-title":"Thromb Haemost"},{"issue":"1","key":"1088_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","volume":"90","author":"PA Merlini","year":"1994","unstructured":"Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61\u20138.","journal-title":"Circulation"},{"issue":"4","key":"1088_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000368747","volume":"129","author":"A Sharma","year":"2014","unstructured":"Sharma A, Garg A, Borer JS, Krishnamoorthy P, Garg J, Lavie CJ, et al. Role of oral factor Xa inhibitors after acute coronary syndrome. Cardiology. 2014;129(4):224\u201332.","journal-title":"Cardiology"},{"key":"1088_CR18","doi-asserted-by":"crossref","unstructured":"Stefanadis C, Antoniou CK, Tsiachris D, Pietri P. Coronary atherosclerotic vulnerable plaque: current perspectives. J Am Heart Assoc. 2017;6(3).","DOI":"10.1161\/JAHA.117.005543"},{"issue":"25","key":"1088_CR19","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","volume":"111","author":"P Libby","year":"2005","unstructured":"Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481\u20138.","journal-title":"Circulation"},{"issue":"3","key":"1088_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1034\/j.1600-0854.2003.8042.x","volume":"16","author":"R Virmani","year":"2003","unstructured":"Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol. 2003;16(3):267\u201372.","journal-title":"J Interv Cardiol"},{"issue":"5","key":"1088_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00001573-200109000-00006","volume":"16","author":"FD Kolodgie","year":"2001","unstructured":"Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16(5):285\u201392.","journal-title":"Curr Opin Cardiol"},{"issue":"2","key":"1088_CR22","first-page":"162","volume":"32","author":"B Estevez","year":"2017","unstructured":"Estevez B, Du X. New concepts and mechanisms of platelet activation signaling. Physiology (Bethesda). 2017;32(2):162\u201377.","journal-title":"Physiology (Bethesda)"},{"issue":"9","key":"1088_CR23","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1182\/blood-2005-02-0618","volume":"107","author":"AJ Reininger","year":"2006","unstructured":"Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006;107(9):3537\u201345.","journal-title":"Blood"},{"issue":"12","key":"1088_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/01.RES.0000267878.97021.ab","volume":"100","author":"ZM Ruggeri","year":"2007","unstructured":"Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100(12):1673\u201385.","journal-title":"Circ Res"},{"issue":"12","key":"1088_CR25","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1161\/01.CIR.94.12.3090","volume":"94","author":"PR Moreno","year":"1996","unstructured":"Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94(12):3090\u20137.","journal-title":"Circulation"},{"issue":"3","key":"1088_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.95.3.594","volume":"95","author":"V Toschi","year":"1997","unstructured":"Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95(3):594\u20139.","journal-title":"Circulation"},{"issue":"9327","key":"1088_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","volume":"360","author":"RF Es van","year":"2002","unstructured":"van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the secondary prevention of events in coronary thrombosis-2 research G. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360(9327):109\u201313.","journal-title":"Lancet"},{"issue":"13","key":"1088_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969\u201374.","journal-title":"N Engl J Med"},{"issue":"5","key":"1088_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1161\/hc0502.103329","volume":"105","author":"LD Fiore","year":"2002","unstructured":"Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105(5):557\u201363.","journal-title":"Circulation"},{"issue":"9386","key":"1088_CR30","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","volume":"362","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362(9386):789\u201397.","journal-title":"Lancet"},{"issue":"14","key":"1088_CR31","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/hrt.2009.177188","volume":"96","author":"P Andrell","year":"2010","unstructured":"Andrell P, Yu W, Gersbach P, Gillberg L, Pehrsson K, Hardy I, et al. Long-term effects of spinal cord stimulation on angina symptoms and quality of life in patients with refractory angina pectoris--results from the European Angina Registry Link Study (EARL). Heart. 2010;96(14):1132\u20136.","journal-title":"Heart"},{"issue":"6","key":"1088_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1093\/eurheartj\/ehl564","volume":"28","author":"C Christersson","year":"2007","unstructured":"Christersson C, Oldgren J, Bylock A, Siegbahn A, Wallentin L. Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial. Eur Heart J. 2007;28(6):692\u20138.","journal-title":"Eur Heart J"},{"key":"1088_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/978-3-642-00663-0_13","volume":"196","author":"M Keisu","year":"2010","unstructured":"Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407\u201318.","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"1088_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1527-3466.2005.tb00176.x","volume":"23","author":"SA Mousa","year":"2005","unstructured":"Mousa SA, Abdel-Razeq HN. Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge? Cardiovasc Drug Rev. 2005;23(4):331\u201344.","journal-title":"Cardiovasc Drug Rev"},{"issue":"22","key":"1088_CR35","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781\u20139.","journal-title":"Eur Heart J"},{"issue":"9683","key":"1088_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"issue":"5","key":"1088_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"CM Gibson","year":"2011","unstructured":"\u2022\u2022 Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161(5):815\u201321 e6 This pivotal trial showed that Rivaroxaban in addition to DAPT post-ACS has great efficacy in reducing cardiovascular events.","journal-title":"Am Heart J"},{"issue":"4","key":"1088_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jacc.2013.03.041","volume":"62","author":"CM Gibson","year":"2013","unstructured":"Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013;62(4):286\u201390.","journal-title":"J Am Coll Cardiol"},{"issue":"10081","key":"1088_CR39","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799\u2013808.","journal-title":"Lancet"},{"issue":"14","key":"1088_CR40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"8","key":"1088_CR41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MCA.0000000000000031","volume":"24","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013;24(8):628\u201335.","journal-title":"Coron Artery Dis"},{"issue":"22","key":"1088_CR42","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Committee AS, Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877\u201385.","journal-title":"Circulation"},{"issue":"8","key":"1088_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"20","key":"1088_CR44","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","volume":"32","author":"PG Steg","year":"2011","unstructured":"Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32(20):2541\u201354.","journal-title":"Eur Heart J"},{"issue":"6","key":"1088_CR45","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1160\/TH13-07-0543","volume":"111","author":"S Goldstein","year":"2014","unstructured":"Goldstein S, Bates ER, Bhatt DL, Cao C, Holmes D, Kupfer S, et al. Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. Thromb Haemost. 2014;111(6):1141\u201352.","journal-title":"Thromb Haemost"},{"issue":"15","key":"1088_CR46","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404\u201313.","journal-title":"N Engl J Med"},{"issue":"1","key":"1088_CR47","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20\u201333.","journal-title":"N Engl J Med"},{"key":"1088_CR48","unstructured":"Janssen. U.S. FDA Approves XARELTO\u00ae (rivaroxaban) to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) 2018 [Available from: https:\/\/www.janssen.com\/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic"},{"issue":"3","key":"1088_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamacardio.2017.5306","volume":"3","author":"M Chiarito","year":"2018","unstructured":"\u2022 Chiarito M, Cao D, Cannata F, Godino C, Lodigiani C, Ferrante G, et al. Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis. JAMA Cardiol. 2018;3(3):234\u201341 This systematic review and meta-analysis study summarizes the results of six trials that included more than 29,000 patients post-ACS and studied the efficacy of adding DOACs in addition to DAPT for the secondary prevention.","journal-title":"JAMA Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1088-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T01:06:26Z","timestamp":1662858386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1088-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1088-x","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"28 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Peter Khalil and Ghazal Kabbach declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"5"}}